These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 27750234

  • 1. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M.
    Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
    [Abstract] [Full Text] [Related]

  • 2. Cases with Refractory Ascites and a Delayed Response to Tolvaptan.
    Hagiwara S, Nishida N, Chishina H, Ida H, Sakurai T, Komeda Y, Kitano M, Kudo M.
    Intern Med; 2016; 55(22):3273-3277. PubMed ID: 27853068
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K.
    World J Gastroenterol; 2017 Aug 07; 23(29):5379-5385. PubMed ID: 28839438
    [Abstract] [Full Text] [Related]

  • 4. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
    Goto A, Terai S, Nakamura M, Matsumoto M, Sakaida I.
    Clin J Gastroenterol; 2015 Feb 07; 8(1):47-51. PubMed ID: 25475138
    [Abstract] [Full Text] [Related]

  • 5. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T.
    Dig Dis; 2018 Feb 07; 36(4):314-321. PubMed ID: 29852495
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG.
    World J Gastroenterol; 2014 Aug 28; 20(32):11400-5. PubMed ID: 25170228
    [Abstract] [Full Text] [Related]

  • 7. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N.
    PLoS One; 2017 Aug 28; 12(3):e0174649. PubMed ID: 28362879
    [Abstract] [Full Text] [Related]

  • 8. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M, Ishihara T, Kato M, Isoai A, Kobayashi R, Torii N, Soneda N, Takei Y.
    Intern Med; 2019 Nov 01; 58(21):3069-3075. PubMed ID: 31292400
    [Abstract] [Full Text] [Related]

  • 9. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    Namba M, Hiramatsu A, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Chayama K.
    J Gastroenterol; 2020 Feb 01; 55(2):217-226. PubMed ID: 31485782
    [Abstract] [Full Text] [Related]

  • 10. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Oku M, Tokushige K, Maenohara S, Ido A.
    J Gastroenterol; 2021 Jan 01; 56(1):54-66. PubMed ID: 32959093
    [Abstract] [Full Text] [Related]

  • 11. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I, Terai S, Nakajima K, Shibasaki Y, Tachikawa S, Tsubouchi H.
    J Gastroenterol; 2017 Feb 01; 52(2):229-236. PubMed ID: 27379386
    [Abstract] [Full Text] [Related]

  • 12. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I.
    Expert Rev Gastroenterol Hepatol; 2014 Jul 01; 8(5):461-70. PubMed ID: 24678622
    [Abstract] [Full Text] [Related]

  • 13. [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].
    Cho HS, Park GT, Kim YH, Shim SG, Kim JB, Lee OY, Choi HS, Hahm JS, Lee MH.
    Taehan Kan Hakhoe Chi; 2003 Dec 01; 9(4):324-31. PubMed ID: 14695699
    [Abstract] [Full Text] [Related]

  • 14. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
    Shimizu K, Doi K, Imamura T, Noiri E, Yahagi N, Nangaku M, Kinugawa K.
    Nephrology (Carlton); 2015 Jun 01; 20(6):405-12. PubMed ID: 25619790
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K, ASCITES 14-Day Administration Study Group.
    J Int Med Res; 2013 Jun 01; 41(3):835-47. PubMed ID: 23685892
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
    Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M.
    World J Gastroenterol; 2017 Dec 07; 23(45):8062-8072. PubMed ID: 29259382
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S, Hamano T, Iwatani H, Mizui M, Kimura Y, Isaka Y.
    Clin Exp Nephrol; 2018 Jun 07; 22(3):550-561. PubMed ID: 29052786
    [Abstract] [Full Text] [Related]

  • 18. [Effect of tolvaptan on ascites due to malignancy].
    Mitsuhashi N, Nemoto S, Satoh Y, Aoki Y, Teranaka R, Sasaki K, Shimazaki R, Ueda A, Nishino H, Akiyama T, Hosokawa I, Yoichi T, Kawamoto J, Kuboki S, Yoshitomi H, Kato A, Shimizu Y, Ohtsuka M, Shimizu H, Miyazaki M.
    Gan To Kagaku Ryoho; 2015 Feb 07; 42(2):201-5. PubMed ID: 25743139
    [Abstract] [Full Text] [Related]

  • 19. [Management of ascites in cirrhotic patients].
    Kurosaki M, Nakanishi H, Izumi N.
    Nihon Shokakibyo Gakkai Zasshi; 2017 Feb 07; 114(1):27-34. PubMed ID: 28070092
    [No Abstract] [Full Text] [Related]

  • 20. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U.
    J Cardiol; 2016 May 07; 67(5):399-405. PubMed ID: 26692119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.